Related Experiment Video
Updated: Jan 8, 2026
A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
Published on: July 12, 2018
Research progress of drugs targeting GPC3 in cancer therapy
Ye-Qin Li1, Yuan Liao1, Wen Zhang2
1College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310014, PR China; Zhejiang Key Laboratory of Green Manufacturing Technology for Chemical Drugs, Deqing 313200, PR China.
Abstract:
Glypican-3 (GPC3) is a cell surface heparan sulfate proteoglycan that is silenced in normal adult tissues but aberrantly re-expressed in several cancers, particularly hepatocellular carcinoma (HCC). Its restricted expression pattern and involvement in oncogenic signaling make it an attractive therapeutic target. Recent advances have led to the development of diverse GPC3-directed modalities, including monoclonal and bispecific antibodies, antibody-drug conjugates (ADCs), immunotoxins, peptides, and chimeric antigen receptor (CAR)-engineered immune cells. These approaches have demonstrated promising efficacy and manageable safety profiles in preclinical and early clinical studies. In addition, post-transcriptional regulation of GPC3 by non-coding RNAs has emerged as a key mechanism influencing its expression and tumorigenic potential, providing novel opportunities for RNA-based therapies. This review summarizes current progress in GPC3-targeted drug development, highlights structure-affinity optimization strategies and discusses translational outcomes and emerging combination strategies. The overview offers an integrated perspective to support the rational design of next-generation GPC3-targeted therapeutics in cancer therapy.
Insights
Glypican-3 (GPC3) is a cancer target re-expressed in tumors. New therapies like antibodies and RNA treatments show promise for cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Drug Development
Background:
- Glypican-3 (GPC3) is a cell surface proteoglycan.
- GPC3 is silenced in normal adult tissues but re-expressed in cancers like hepatocellular carcinoma (HCC).
- Its specific expression pattern and role in cancer signaling make it a therapeutic target.
Purpose of the Study:
- To review current progress in GPC3-targeted drug development.
- To highlight structure-affinity optimization strategies for GPC3-therapeutics.
- To discuss translational outcomes and combination strategies for GPC3-targeted cancer therapy.
Main Methods:
- Review of diverse GPC3-directed therapeutic modalities.
- Analysis of preclinical and early clinical study data.
- Exploration of non-coding RNA regulation of GPC3.
Main Results:
- Development of GPC3-targeted therapies including antibodies, ADCs, immunotoxins, peptides, and CAR-T cells.
- Promising efficacy and manageable safety profiles observed in early studies.
- Identification of non-coding RNAs as key regulators of GPC3 expression.
Conclusions:
- GPC3-targeted therapies demonstrate significant therapeutic potential in cancer.
- Structure-affinity optimization and combination strategies are crucial for next-generation therapeutics.
- RNA-based therapies targeting GPC3 offer novel treatment avenues.
More Related Videos
07:41A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Related Concept Videos
01:15G Protein-coupled Receptors
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:15Drugs that Stabilize Microtubules